



# BAISHIDENG PUBLISHING GROUP INC

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**Manuscript NO:** 32240

**Title:** The Use of Proton Pump Inhibitors in General Practice

**Reviewer's code:** 03648129

**Reviewer's country:** Spain

**Science editor:** Ze-Mao Gong

**Date sent for review:** 2017-02-09

**Date reviewed:** 2017-02-21

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

First of all, I would like to congratulate you for the article. My comments are:

**INTRODUCTION** - What does OAT mean? It is oral anticoagulant therapy but you should write the meaning in the introduction. - "PPI reimbursement resulted applicable to 69.3% of the PPI users, but the potential for meeting eligibility requirements for reimbursement of PPI prescriptions was identified in the non PPI users for the treatment of peptic or reflux disease (8.5%) and for the protection of gastric damage caused by NSAIDS (6.1%)" : it is a complex sentence, it is difficult to fully understand the meaning of the paragraph. - "Patients who are potentially eligible for reimbursement are older, diagnosed with arthropathy and heart disease more frequently and more frequently receive NSAID and ASA prescriptions compared with PPI users who do not satisfy eligibility requirements": change one "more frequently" for a synonymous such as "more common".

**MATERIALS AND METHODS** - Please could you specify the lapse of time you have registered for the study? - Which is the definition of "heart disease"? Does it include arrhythmia, heart attack, heart failure, valvulopathy?



## BAISHIDENG PUBLISHING GROUP INC

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

<http://www.wjgnet.com>

---

RESULTS - "1939 out of 6322 patients do therefore not comply with PPI prescription suitability according to the Italian Drug Agency": I think it is important to add the percentage of 1939 out of 6322 patients. - In Figure 1: "PPI-users with refundable drug according the Italian Drug Agency (light grey) because of protection of gastric damage by NSAIDS, PPI-users without identifiable refundable drug (black), non PPI-users with identifiable need of the protection of gastric damage by NSAIDS (dark grey), and the remaining population (white)" : It is important to write down the percentages. And also in this figure it would be better write PPI-users and the percentages of the three indications: 1)the prevention of serious complications of the upper gastrointestinal tract in patients in chronic treatment with NSAIDS or in antiaggregant therapy with low doses of ASA 2) duration of treatment 4 weeks (occasionally 6 weeks): duodenal or gastric ulcer, in association with drugs eradicating the infection; GERD with or without esophagitis (first episode) 3) duration of treatment extended to reevaluate after one year: Zollinger-Ellison syndrome; relapsing duodenal or gastric ulcer; GERD with and without esophagitis (relapsing) And then PPI-users without identifiable refundable drug and non PPI-users with indication of PPI. DISCUSSION - "The analysis of a database of over 40,000 patients allows us to highlight the fact that long-term prescription of PPI drugs is found in almost 15% of the population. These data are not dissimilar to those available on the whole Italian population (5)": Could you compare also this percentage of use of PPI drugs with its use in other countries? - "It is important to note that the current reimbursement eligibility criteria were drafted more than 10 years ago and without an updated version it is difficult and disadvantageous to use PPIs in clinical conditions which are known to potentially cause serious gastrointestinal bleeding, such as the use of new strategies in antiplatelet and anticoagulation therapy (21) and the use of SSRIs especially in conjunction with ASA and NSAIDS (22)": You have to write the meaning of SSRIs. It is also a large and complex sentence, try to divided in two or simplify it. - You should acknowledge that another limitation of the study is that you don't know if patients non-IPP users with GERD are taking others drugs like ranitidine.

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**Manuscript NO:** 32240

**Title:** The Use of Proton Pump Inhibitors in General Practice

**Reviewer's code:** 00034127

**Reviewer's country:** United States

**Science editor:** Ze-Mao Gong

**Date sent for review:** 2017-02-09

**Date reviewed:** 2017-02-28

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> [ Y ] Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> [ Y ] Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> [ ] High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> [ ] Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> [ Y ] No	<input type="checkbox"/> [ ] Minor revision
		BPG Search:	<input type="checkbox"/> [ ] Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> [ Y ] No	

### COMMENTS TO AUTHORS

This is an interesting retrospective analysis of PPI use in Italy assessing adherence to the indications of the guidelines issued by the Italian Drug Agency. 1. The statement whether this study approved by Ethics Committee/Institutional Review Board should be included in Material and Methods section.



# BAISHIDENG PUBLISHING GROUP INC

7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Pharmacology and Therapeutics

**Manuscript NO:** 32240

**Title:** The Use of Proton Pump Inhibitors in General Practice

**Reviewer's code:** 00058696

**Reviewer's country:** United States

**Science editor:** Ze-Mao Gong

**Date sent for review:** 2017-02-21

**Date reviewed:** 2017-03-03

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input checked="" type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

### COMMENTS TO AUTHORS

This manuscript has been carefully examined. Major concerns include: 1) What is the authors' hypothesis? 2) There are multiple manuscript that demonstrate that physicians do not follow practice guidelines. 3) Table 1 should be in the MATERIALS (not MATHERIALS) AND METHODS section not in the INTRODUCTION. 4) The ABSTRACT is full of abbreviations that should be first defined. 5) The authors provide no support for their conclusion "for decreasing inappropriate use of PPI drugs ... by involving all interested parties". 6) "Packs of PPIs" have not been defined, e.g. what is the number of doses? 7) The authors have not clarified the clinical significance of the findings in their study.